Clinical trials: Malignant Brain Glioma
Malignant Brain Tumor, Brain Stem Glioma,
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
The purpose of this study is to establish the recommended dose/Maximum Tolerated Dose (MTD) of Tarceva in children as single agent and in combination with radiation therapy
- Trial name
- NCT00418327
- Testing
- Tarceva (Erlotinib Hydrochloride)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Glioma
Enhanced Detection in Glioma Excision
The purpose of this study is to determine whether use of an ultra-high sensitivity camera with enhanced imaging technology can be used during surgery to detect areas of brain tissue affected by diffuse glioma, a type of brain…
- Trial name
- EDGE (NCT04556929)
- Testing
- Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera, Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera, Biopsies
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Oxford
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Brain Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with anaplastic astrocytomas.
- Trial name
- NCT00002620
- Testing
- carmustine, chemotherapy, mitolactol
- Where
- 14 sites in Austria, Belgium and 6 more
- Volunteers
- 212 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma, Gliosarcoma
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Primary Objective To determine maximum tolerated dose \& dose limiting toxicity of Zactima when combined w standard dosing of imatinib mesylate \& hydroxyurea among pts w recurrent malignant glioma who are on \& not on…
- Trial name
- NCT00613054
- Testing
- Zactima, Gleevec, Hydroxyurea
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Annick Desjardins
Malignant Glioma, Glioblastoma
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with gliomas that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
- Trial name
- NCT01454596
- Testing
- Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Venous Thromboembolism, Brain Tumors
The Roles of Tissue Factor in Malignant Gliomas
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
- Trial name
- NCT00201903
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Malignant Brain Neoplasm, Malignant Glioma
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery.
- Trial name
- NCT03510208
- Testing
- Near-Infrared Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Stanford University
Glioblastoma Multiforme, Anaplastic Astrocytoma
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
This Phase 1 study in patients with newly diagnosed malignant glioma is designed to determine the highest dose of IL13-PE38QQR that can be safely administered by Convection Enhanced Delivery (CED) to the area around the tumor…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma
- Trial name
- NCT00089427
- Testing
- IL13-PE38QQR, Surgery for placement, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- INSYS Therapeutics Inc
Brain and Central Nervous System Tumors
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells.
- Trial name
- NCT00004024
- Testing
- aldesleukin, autologous tumor cell vaccine, muromonab-CD3
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Malignant Glioma of Brain, Glioblastoma
LITT Palliative Treatment for Patients With Malignant Gliomas
The purpose of this study is to to describe the effect of a palliative regimen consisting of Laser Interstitial Thermal Therapy (LITT) on distress, quality of life (QOL), neurocognition, days in the hospital, patient disposition…
- Trial name
- NCT03176160
- Testing
- Palliative regimen consisting of LITT
- Where
- United States
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Metastatic Cancer
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients…
- Trial name
- NCT00009854
- Testing
- carmustine in ethanol, conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Direct Therapeutics
GLIOBLASTOMA MULTIFORME, Brain Neoplasm
BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor
The goal of this study is to create a comprehensive database of Magnetic Resonance Imaging (MRI) and of pathology for patients with brain tumors.
- Trial name
- CONDR (NCT01124461)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Washington University School of Medicine
Glioma, Malignant, Gliosarcoma
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
The purpose of this pilot study is to determine the safety, tolerability, and the maximum tolerated dose intranasal administration of temozolomide (TMZ) as a single agent in Treatment on the patients with GBM.
- Conditions
- Glioma, Malignant, Gliosarcoma, Astrocytoma of Brain
- Trial name
- NCT04091503
- Testing
- Intranasal Modified Temozolomide
- Where
- 3 sites in Bosnia and Herzegovina, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Center Trials & Treatment Europe
Brain Neoplasm, Malignant Glioma
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery.
- Trial name
- NCT02855086
- Testing
- Cetuximab, Cetuximab-IRDye 800CW, Tumor resection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Eben Rosenthal
Glioblastoma
Proteome-based Personalized Immunotherapy of Glioblastoma
Trial Hypothesis: Acute, progressing lethal neurooncological process can be transferred into chronic and non-lethal, the survival rates and life quality can be improved by of control of tumor cells (TCs) quantity and targeted…
- Trial name
- NCT01759810
- Testing
- Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- NeuroVita Clinic
Glioma, Brain Tumor
GW572016 to Treat Recurrent Malignant Brain Tumors
This study will examine whether an experimental drug called GW572016 can delay tumor growth in patients with glioblastoma multiforme (GMB, a malignant brain tumor).
- Conditions
- Glioma, Brain Tumor, Glioblastoma Multiforme, GBM
- Trial name
- NCT00107003
- Testing
- lapatinib ditosylate, Adjuvant therapy, Conventional surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
RATIONALE: Vaccines made from a person's white blood cells and tumor cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00107185
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma Multiforme, Glioma
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors.
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02502708
- Testing
- Indoximod, Temozolomide, Conformal Radiation
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- NewLink Genetics Corporation
Brain and Central Nervous System Tumors
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006025
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- 9 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients who have progressive…
- Trial name
- NCT00003616
- Testing
- irinotecan hydrochloride
- Where
- 10 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins